仙桃锚索价格 保住海选分子的“号码”，药明康德解开70年经典响应的应用艰巨 | Bilingual

往时几十年间仙桃锚索价格，药物发现的式发生了刻变化。

组化学的兴起，使接头东说念主员约略在短时辰内成海量分子；通量筛选（HTS）和DNA编码化物库（DEL）等期间的演进，则不断改写药物筛选的率与界限。

跟着越来越多传统靶点被充分挖掘、新兴疗方式不断涌现，药物发现的挑战不仅仅“找到多分子”，在于找到各类的分子。

要是进入筛选体系的分子缺少弥散的结构各类，再大的化物库，也可能仅仅对有限化学空间的重叠探索。因此，奈何遮掩丰富的化学空间、复杂的分子结构，成为拓展药物发现界限的枢纽命题。

在这配景下，类出生于近70年前的经典化学响应，正以种新的式从头进入东说念主们的视线。

从多步成到步构建

长期以来，复杂小分子的构建度依赖多步响应旅途：接头东说念主员节约单结构起程，次序邻接不同片断，每步齐在前步完成后才能伸开。经多轮响应与纯化，料想打算分子才终成型。

这种“搭积木”式的迟缓成法诚然可靠，却难以快速生成普遍结构互异的新分子。

1958年，个影响远的新想法悄然出生。在德国慕尼黑大学的执行室里，化学Ivar Ugi不雅察到个不同寻常的安详。

当胺、醛（或酮）、羧酸和异腈这4类组分被同期加入同个响应体系后，它们并未按照东说念主们熟悉的旅途迟缓构建居品，而是通过系列一语气发生的响应过程，步生成结构复杂的料想打算分子。

这响应自后被定名为Ugi响应。

以今天的视角来看，这么的多组分响应不仅能省去普遍中间步骤，而况原料组机动，只需换其中随性种组分，就约略快速生成新的分子结构，成心于探索宽阔的化学空间。

不外，在出生后的数十年里，Ugi响应并未立即成为药示寂学域的主流用具。直到20世纪90年代，跟着组化学兴起，东说念主们开动寻求的法来构建和蔓延化物库，此时Ugi响应的实在后劲才得到开释。凭借步生成复杂结构的势，这类响应依然发展为构建化物库、成药物骨架的紧迫用具。

当经典化学遇上DEL

一样在上世纪90年代，另项自后刻影响药物发现的期间也开动萌芽。

1992年，DNA编码化物库的意见被次建议。

DEL的核心想路并不复杂：为每个化物附上段特的DNA序列，特殊于为每个分子赋予属编码标签。接头东说念主员随后不错将多达数十亿个化物混在同个体系中，同期对料想打算卵白进行筛选。筛选放胆后，通过读取标签，接头东说念主员就能快速识别出约略与料想打算卵白结的候选分子。

DEL期间大幅进步了化物筛选界限，并逐步成为当代药物发现的紧迫平台期间。

连年来，跟着DEL期间的发展，奈何让DEL遮掩宽阔的化学空间，成为接头东说念主员温雅的焦点问题。

在这配景下，Ugi响应与DEL期间的互补势表示。凭借生成结构各类的势，Ugi响应约略将多复杂化学结构引入DEL，从而拓展DEL可探索的化学空间。

但问题在于，两项期间诚然理念契仙桃锚索价格，在期间层面却并不兼容。

在DEL期间中，旦化物佩带的编码标签受损，其对应的身份信息便会丢失。而好多常见的有机响应条目，举例温、强酸强碱、金属催化以至部分有机试剂，齐可能致这编码体系受损或失活。

Ugi响应一样面对这挑战。经典Ugi体系依赖异腈这枢纽组分，而异腈蒸发强、响应条目不够仁和，而况容易产生响应。这些身分齐会提DEL体系中的毁感冒险，从而放胆其在DEL中的应用。

奈何既保留Ugi响应的势，又让它约略实在兼容DEL体系？

药明康德生物学平台（WuXi Biology）接头团队在近期发表的项接头中给出了谜底。

新接头：寻找兼容新旅途

异腈带来的兼容挑战，成为接头团队先需要处分的问题。他们试图寻找异腈的替代案，从而构建条仁和、适DEL体系的响应旅途。

为此，接头团队将眼力投向了类名为三甲基硅氰（TMSCN）的试剂。

TMSCN约略在定条目下模拟异腈参与Ugi类响应。在水相条目下，TMSCN约略自觉响应变成活中间体，钢绞线并参与后续响应过程。

基于这想路，接头团队构建了套新的兼容响应体系。

比较于传统异腈体系，这联想不仅藏匿了异腈在健硕和操作上的局限，而且需稀零催化剂即可进行，响应条目也加仁和。

高出的接头标明，该响应的底物适用范围广，多种芳醇醛和杂环脒类均能参与响应。诈欺这政策，接头团队构建出系列稠咪唑并吡啶（imidazopyridine）骨架。

咪唑并吡啶长期受到药物研发域温雅。其丰富的三维构型和氢键互相作用，有助于增强小分子与靶卵白的结才略，已应用于多个获批药物以及、症、核心神经系统等域的在研管线中。

值得郑重的是，在响应条目化过程中，该体系对DNA编码标签施展出致密的兼容，未不雅察到彰着毁伤，为其在DEL体系中的实质应用奠定了枢纽基础。

在此基础上，团队完了了从Ugi响应到后续修饰，再到编码标签邻接的一语气多步经过。这意味着，该法不仅能完了单步骤的响应考据，具备融入实在DEL建库经过的后劲。▲接头表现图（图片起首：参考府上[1]）

当新的期间平台出现，那些曾领受限于时期条目的经典响应，也可能以新的体式从头开释后劲。该接头不仅为经典Ugi响应提供了条适用于DEL体系的新旅途，也为DEL平台引入了类具有紧迫药理价值的骨架，使接头东说念主员约略探索多往时难以涉及的分子结构。

DEL平台的捏续拓展

这项效果背后，是药明康德多年来围绕DEL期间捏续插足与才略设置的蕴蓄。

药明康德生物学平台于2018年从起步设置DEL平台，将这项也曾门槛的期间，发展为高大接头东说念主员约略放肆使用的药物发现用具。

在数年的才略设置中，药明康德生物学平台依然构建了过1400个DEL化物库，提供了过1.1万亿个DEL分子，每年为客户筛选数十亿别的化物。同期，团队还完成了100种DNA兼容响应，可赋能改动骨架生成的需求，捏续拓展DEL可遮掩的化学空间。

如今，药明康德已设置起纯熟完善的DEL期间平台，并不时围绕各类新骨架引入、兼容响应等向布局仙桃锚索价格，捏续赋能环球作伙伴提供针对多种分子类型的新药发现。举例，从RNA靶向筛选到双分子发现，DEL正从传统筛选迟缓蔓延至多新兴药物发现域。

在药明康德，DEL平台已成为其新药发现体系的基石之。药明康德生物学平台将DEL与片断筛选（Fragment Screening）、通量筛选（HTS）等期间度融，造了个多维协同的综发现平台，为客户提供系统处分案、进步早期药物发现告捷率。

从DEL平台的捏续进化，到让经典响应甘愿腾达，药明康德正不断拓展药物发现的空间与才略，让每位新药研发的探路者多条通往止境的路，助力环球作伙伴快地将新药带到患者身边。

▲欲了解WuXi Biology奈何赋能药物研发，请长按扫描上二维码，与药明康德生物学业务平台考虑 ]article_adlist-->

Unlocking Chemical Space: How WuXi AppTec Leverages DEL to Advance Drug Discovery

By adapting established reactions and introducing new molecular scaffolds into DNA-Encoded Library (DEL) systems, WuXi AppTec expands the chemical space available for molecular exploration, enabling clients to advance drug discovery.

DEL Innovation Expands Chemical Space

Over the past several decades, advances in technologies such as high-throughput screening (HTS) and DEL have expanded the scope of drug discovery. As the field strives to explore broader regions of chemical space, expanding molecular diversity has become a central focus.

As the industry seeks to explore broader regions of chemical space, the team at WuXi Biology, a business unit of WuXi AppTec, continues to expand the capabilities of DEL-based discovery through the development of compound libraries, DNA-compatible reactions, and enabling technologies.

Since its introduction in 1992, DEL has become an important technology for early drug discovery. By attaching a unique DNA tag to each compound, researchers can screen billions of molecules simultaneously against a biological target and rapidly identify potential binders through reading the tag.

However, the value of DEL is not determined solely by library size. The diversity of molecular structures contained within those libraries is equally important. Even extremely large libraries may repeatedly sample similar regions of chemical space if the underlying chemistry remains limited.

As a result, introducing novel chemical scaffolds and expanding the range of reactions compatible with DEL have become key challenges across the industry.

Adapt Classical Chemistry for Modern Drug Discovery Platforms

Many classical chemical reactions predate modern drug discovery platforms. Now, WuXi Biology bridges this gap by adapting classical chemistry for compatibility with contemporary screening technologies.

One example is the Ugi reaction, first discovered by chemist Ivar Ugi in 1958. Unlike traditional stepwise synthesis approaches, the Ugi reaction enables multiple building blocks to be assembled into a complex molecule within a single reaction process.

Because different reaction components can be readily exchanged, the Ugi reaction offers an efficient way to generate structurally diverse molecules and has become an important tool for combinatorial chemistry and compound library construction.

Despite these advantages, the reaction has faced limitations in DEL applications because traditional Ugi chemistry relies on isocyanides and reaction conditions that are not always readily transferable to DEL systems.

This created an opportunity to revisit a well-established reaction through the lens of modern drug discovery needs.

Develop a New DNA-Compatible Strategy

To further expand the chemical space accessible through DEL, the WuXi Biology team developed a new Ugi-type strategy that enables the benefits of Ugi chemistry to be applied within DEL workflows.

The research team explored trimethylsilyl cyanide (TMSCN) as an alternative reagent capable of participating in Ugi-type transformations under mild aqueous conditions.

The resulting reaction system addressed several practical limitations associated with conventional Ugi chemistry while enabling the generation of fused imidazopyridine scaffolds, a class of structures that has attracted considerable interest due to its presence in approved therapies and pipelines across oncology, inflammation, and central nervous system disorders.

Importantly, the reaction conditions preserved the integrity of encoded molecules throughout the process, providing a foundation for practical application within DEL systems.

The researchers further demonstrated a workflow that connected Ugi-type chemistry, downstream modification, and tag incorporation, highlighting the potential for integration into real-world DEL library construction processes.Image source: Reference [1]

Expand the Capabilities of DEL-Based Drug Discovery

Building on years of platform development, WuXi Biology continues to expand DEL-based drug discovery by developing new libraries, introducing novel scaffold-generating chemistry, and broadening the range of molecular structures that can be explored through DEL.

Since establishing its DEL platform in 2018, WuXi Biology has built more than 1,400 DEL libraries containing over 1.1 trillion encoded molecules. The team has also developed more than 100 DNA-compatible reactions that support the introduction of novel chemical scaffolds and continued expansion of accessible chemical space.

Today, the DEL platform supports discovery efforts across a growing range of applications. Beyond traditional small-molecule screening, DEL is increasingly being applied to emerging areas such as RNA-targeted discovery and bifunctional molecule research.

As part of WuXi Biology’s broader discovery capabilities, DEL is integrated with technologies such as HTS and fragment screening to provide a comprehensive toolkit, enabling clients to efficiently identify and advance promising leads for drug discovery programs.

Key Takeaways

WuXi AppTec expands chemical space for drug discovery through continuous innovation in DEL technologies.

The team at WuXi Biology, a business unit of WuXi AppTec, developed a novel Ugi-type reaction strategy that enables structurally diverse scaffolds to be incorporated into DEL workflows, translating classical reactions into practical tools for modern drug discovery platforms.

Since establishing its DEL platform in 2018, WuXi Biology has established more than 1,400 DEL libraries containing over 1.1 trillion encoded molecules to support early-stage drug discovery.

WuXi Biology has developed more than 100 DNA-compatible reactions to expand the range of chemical transformations available for DEL applications.

WuXi Biology integrates DEL with HTS and fragment screening, supporting emerging applications such as RNA-targeted discovery and bifunctional molecule research.

参考府上：

[1] Guo et al., Ugi-Type Reaction Enables Access to Fused Imidazole Derivatives for DNA-Encoded Library Technology. Bioconjug Chem. 2026 Apr 15;37(4):675-683. doi: 10.1021/acs.bioconjchem.5c00655责声明：本文仅作信断相通之主张，文中不雅点不代表药明康德态度，亦不代表药明康德撑捏或反对文中不雅点。本文也不是疗案荐。如需赢得疗案指，请赶赴正规病院就诊。

版权证实：接待个东说念主转发至一又友圈，谢媒体或机构未经授权以任何体式转载至其他平台。转载授权请在「药明康德」微信公众号文告“转载”，获取转载应知。

共享，点赞，在看，聚焦环球生物医药健康改动 ]article_adlist--> 海量资讯、解读，尽在财经APP 天津市瑞通预应力钢绞线有限公司相关词条:离心玻璃棉     塑料挤出机     钢绞线厂家    铝皮保温    pvc管道管件胶

1.本网站以及本平台支持关于《新广告法》实施的“极限词“用语属“违词”的规定，并在网站的各个栏目、产品主图、详情页等描述中规避“违禁词”。
2.本店欢迎所有用户指出有“违禁词”“广告法”出现的地方，并积极配合修改。
3.凡用户访问本网页，均表示默认详情页的描述，不支持任何以极限化“违禁词”“广告法”为借口理由投诉违反《新广告法》，以此来变相勒索商家索要赔偿的违法恶意行为。